ethyl N-(2-thiophenecarbonylmethyl)oxamate | 202595-26-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl N-(2-thiophenecarbonylmethyl)oxamate
• 英文别名: Ethyl {[2-oxo-2-(thiophen-2-yl)ethyl]carbamoyl}formate；ethyl 2-oxo-2-[(2-oxo-2-thiophen-2-ylethyl)amino]acetate
• CAS: 202595-26-4
• 化学式: C₁₀H₁₁NO₄S
• 分子量: 241.268
• InChiKey: VWHZWEJMHYHXBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl N-(2-thiophenecarbonylmethyl)oxamate 在 三氯氧磷 作用下， 反应 1.5h， 生成 ethyl 5-(thiophen-2-yl)oxazole-2-carboxylate
  参考文献：
  名称：

  1,3-Oxazole-based selective picomolar inhibitors of cytosolic human carbonic anhydrase II alleviate ocular hypertension in rabbits: Potency is supported by X-ray crystallography of two leads

  摘要：

  Two lead 1,3-oxazole-based carbonic anhydrase inhibitors (CAIs) earlier identified as selective, picomolar inhibitors of hCA II (a cytosolic target for treatment of glaucoma) have been investigated further. Firstly, they were found to be conveniently synthesized on multigram scale, which enables further development. These compounds were found to be comparable in efficacy to dorzolamide eye drops when applied in the eye drop form as well. Finally, the reasons for unusually high potency of these compounds became understood from their high-resolution X-ray crystallography structures. These data significantly expand our understanding of heterocycle-based primary sulfonamides, many of which have recently emerged from our labs - particularly, from the corneal permeability standpoint. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2017.06.054
• 作为产物：
  描述：

  2-溴-1-(2-THIENYL)-1-ETHANONE 在 吡啶 、 乌洛托品 作用下， 以 乙醇 为溶剂， 反应 27.0h， 生成 ethyl N-(2-thiophenecarbonylmethyl)oxamate
  参考文献：
  名称：

  Probing the ‘bipolar’ nature of the carbonic anhydrase active site: Aromatic sulfonamides containing 1,3-oxazol-5-yl moiety as picomolar inhibitors of cytosolic CA I and CA II isoforms

  摘要：

  A series of potent inhibitors of human carbonic anhydrase (CA) isoforms I and II has been prepared via a direct, chemoselective sulfochlorination of a range of 1,3-oxazolyl benzenes and thiophenes, followed by primary sulfonamide synthesis. The latter functionality is a known zinc-binding group (ZBG) responsible for anchoring the inhibitors to the CA's zinc metal ion. The compound's periphery as well as the overall scaffold geometry was designed to enable optimal interactions with the two distinct sides of the enzyme's active site, one of which is lined with hydrophobic residues and while the other is predominantly hydrophilic. As a result, several compounds inhibiting the therapeutically important cytosolic CA I and CA II in picomolar range have been identified. These compounds are one of the most potent CA inhibitors identified to-date. Not only the remarkable (>10 000-fold), cytosolic CA I and CA II selectivity vs. the membrane-bound CA IX and CA XII isoforms, but also the pronounced CA II/I selectivity observed in some cases, allow considering this series as a set of isoform-selective chemical biology tools and promising starting points for drug candidate development. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.06.022

文献信息

• Heterocyclic compounds, their production and use
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP1270571A1

  公开（公告）日：2003-01-02

  Heterocyclic compounds represented by general formula (I): wherein R stands for an optionally substituted aromatic heterocyclic group; X stands for oxygen atom, an optionally oxidized sulfur atom, -C(=O) or - CH(OH)-; Y stands for CH or N; m denotes an integer of 0 to 10; n denotes an integer of 1 to 5; the cyclic group: stands for an optionally substituted aromatic azole group; and ring A may be further substituted, or salts thereof. The compound (I) possesses action of inhibiting tyrosine kinase and is useful as an antitumor agent.

  通式 (I) 所代表的杂环化合物： 其中 R 代表任选取代的芳香杂环基团； X 代表氧原子、任选氧化的硫原子、-C(=O) 或-CH(OH)-； Y 代表 CH 或 N； m 表示 0 至 10 的整数； n 表示 1 至 5 的整数； 环状基团： 代表任选取代的芳香族唑基；环 A 可进一步被取代、 或其盐类。 化合物（I）具有抑制酪氨酸激酶的作用，可用作抗肿瘤药物。
• US6211215B1
  申请人：——

  公开号：US6211215B1

  公开（公告）日：2001-04-03
• Probing the ‘bipolar’ nature of the carbonic anhydrase active site: Aromatic sulfonamides containing 1,3-oxazol-5-yl moiety as picomolar inhibitors of cytosolic CA I and CA II isoforms
  作者：Mikhail Krasavin、Mikhail Korsakov、Mikhail Dorogov、Tiziano Tuccinardi、Nurcan Dedeoglu、Claudiu T. Supuran

  DOI：10.1016/j.ejmech.2015.06.022

  日期：2015.8

  A series of potent inhibitors of human carbonic anhydrase (CA) isoforms I and II has been prepared via a direct, chemoselective sulfochlorination of a range of 1,3-oxazolyl benzenes and thiophenes, followed by primary sulfonamide synthesis. The latter functionality is a known zinc-binding group (ZBG) responsible for anchoring the inhibitors to the CA's zinc metal ion. The compound's periphery as well as the overall scaffold geometry was designed to enable optimal interactions with the two distinct sides of the enzyme's active site, one of which is lined with hydrophobic residues and while the other is predominantly hydrophilic. As a result, several compounds inhibiting the therapeutically important cytosolic CA I and CA II in picomolar range have been identified. These compounds are one of the most potent CA inhibitors identified to-date. Not only the remarkable (>10 000-fold), cytosolic CA I and CA II selectivity vs. the membrane-bound CA IX and CA XII isoforms, but also the pronounced CA II/I selectivity observed in some cases, allow considering this series as a set of isoform-selective chemical biology tools and promising starting points for drug candidate development. (C) 2015 Elsevier Masson SAS. All rights reserved.
• 1,3-Oxazole-based selective picomolar inhibitors of cytosolic human carbonic anhydrase II alleviate ocular hypertension in rabbits: Potency is supported by X-ray crystallography of two leads
  作者：Marta Ferraroni、Laura Lucarini、Emanuela Masini、Mikhail Korsakov、Andrea Scozzafava、Claudiu T. Supuran、Mikhail Krasavin

  DOI：10.1016/j.bmc.2017.06.054

  日期：2017.9

  Two lead 1,3-oxazole-based carbonic anhydrase inhibitors (CAIs) earlier identified as selective, picomolar inhibitors of hCA II (a cytosolic target for treatment of glaucoma) have been investigated further. Firstly, they were found to be conveniently synthesized on multigram scale, which enables further development. These compounds were found to be comparable in efficacy to dorzolamide eye drops when applied in the eye drop form as well. Finally, the reasons for unusually high potency of these compounds became understood from their high-resolution X-ray crystallography structures. These data significantly expand our understanding of heterocycle-based primary sulfonamides, many of which have recently emerged from our labs - particularly, from the corneal permeability standpoint. (C) 2017 Elsevier Ltd. All rights reserved.